General Tests, Processes and Apparatus

Total Page:16

File Type:pdf, Size:1020Kb

General Tests, Processes and Apparatus GENERAL TESTS, PROCESSES AND APPARATUS General Tests, Processes and Apparatus includes common general test method. methods for tests, useful test methods for quality recognition of drugs and other articles related to them. Unless otherwise 1. Chemical Methods speciˆed, the procedures for acid-neutralizing capacity deter- mination of gastrointestinal medicines, alcohol number de- termination, ammonium determination, arsenic determina- tion, atomic absorption spectrophotometry, test for bacterial 1.01 Alcohol Number endotoxins, boiling point determination, distilling range de- termination, chloride determination, conductivity measure- Determination ment, congealing point determination, determination of bulk Alcohol Number Determination represents the number of and tapped densities, digestion test, disintegration test, disso- milliliters of ethanol at 159C obtained from 10 mL of tin- lution test, endpoint detection in titrimetry, test of extracta- cture or other preparations containing ethanol by the follow- ble volume for injection, ‰ame coloration, ‰uorometry, ing procedures. foreign insoluble matter test for injections, gas chro- matography, heavy metals determination, test for glass Method 1 Distilling method containers for injections, infrared spectrophotometry, This is a method to determine the Alcohol Number by insoluble particulate matter test for injections, insoluble reading the number of milliliters of ethanol distillate at 159C particulate matter test for ophthalmic solutions, iron deter- obtained from 10 mL of a sample measured at 159Cbythe mination, liquid chromatography, loss on drying determina- following procedures. tion, loss on ignition determination, melting point determina- (1) Apparatus tion, test for metal particles in ophthalmic ointments, Use hard glass apparatus as illustrated in Fig. 1.01-1. methanol determination, microbial assay for antibiotics, test Ground glass may be used for the joints. for microbial limit, test for microbial limit for crude drugs, (2) Reagent mineral oil determination, nitrogen determination, nuclear Alkaline phenolphthalein solution: To 1 g of phenolphtha- magnetic resonance spectroscopy, optical rotation determi- lein add 7 mL of sodium hydroxide TS and water to make 100 nation, osmolarity determination, oxygen ‰ask combustion mL. method, particle size distribution test for preparations, pH (3) Procedure determination, test for plastic containers, powder particle Transfer 10 mL of the sample preparation, accurately density determination, powder particle size determination, measured at 15 ± 29C, to the distilling ‰ask A, add 5 mL of test for pyrogen, qualitative test, test for readily carbonizable water and boiling chips. Distil ethanol carefully into the substances, refractive index determination, residual solvents glass-stoppered, volumetric cylinder D. test, residue on ignition determination, test for rubber By reference to Table 1.01-1, a suitable volume of distillate closure for aqueous infusions, speciˆc gravity and density (mL) should be collected, according to the content of ethanol determination, speciˆc surface area determination, test for in the sample preparation. sterility, sulfate determination, thermal analysis, thin-layer Prevent bumping during distillation by rendering the chromatography, test for total organic carbon, ultraviolet- sample strongly acidic with phosphoric acid or sulfuric acid, visible spectrophotometry, uniformity of dosage units (test or by adding a small amount of para‹n, beeswax or silicone for content uniformity, mass variation test), viscosity resin before starting the distillation. determination, vitamin A assay, water determination, and When the samples contain the following substances, carry X-ray powder diŠraction are performed as directed in the out pretreatment as follows before distillation. corresponding articles under the General Tests, Processes (i) Glycerin: Add su‹cient water to the sample so that and Apparatus. The tests for melting point of fats, congeal- the residue in the distilling ‰ask, after distillation, contains at ing point of fatty acids, speciˆc gravity, acid value, saponiˆ- least 50z of water. cation value, ester value, hydroxyl value, unsaponiˆable mat- (ii) Iodine:Decolorizethesamplewithzincpowder. ter and iodine value of fats and fatty oils are performed as (iii) Volatile substances: Preparations containing ap- directed in the corresponding items under Fats and Fatty Oils preciable proportions of essential oil, chloroform, diethyl Test, and sampling, preparation of sample for analysis, ether or camphor require treatment as follows. Mix 10 mL of microscopic examination, purity test, loss on drying, total the sample, accurately measured, with 10 mL of saturated ash, acid-insoluble ash, extract content, and essential oil con- sodium chloride solution in a separator, add 10 mL of tent of crude drugs are performed as directed in the corre- petroleum benzin, and shake. Collect the separated aqueous sponding items under Crude Drugs Test. layer. The petroleum benzin layer was extracted with two 5 Thenumberofeachtestmethodisacategorynumber mL portions of saturated sodium chloride solution. Combine given individually. The number in blackets (<>)appeared the aqueous layers, and distill. According to the ethanol in monograph indicates the number corresponding to the content in the sample, collect a volume of distillate 2 to 3 mL 17 18 Alcohol Number Determination / General Tests JP XV Table 1.01-1 to 2 drops of alkaline phenolphthalein solution, and shake vigorously. If the aqueous layer shows no white turbidity, Ethanol content in Distillate thesample(volz) to be collected (mL) agitate the distillate with additional potassium carbonate. After allowing to stand in water at 15 ± 29C for 30 minutes, more than 80 13 read the volume of the upper reddish ethanol layer in mL, 80 – 70 12 and regard it as the Alcohol Number. If there is no clear 70 – 60 11 boundary surface between these two layers, shake vigorously 60 – 50 10 50 – 40 9 after addition of a few drops of water, then observe in the 40 – 30 8 same manner. less than 30 7 Method 2 Gas chromatography This is a method to determine the alcohol number by deter- mining ethanol (C2H5OH) content (volz) from a sample measured at 159C by the following procedures. (1) Reagent Ethanol for alcohol number: Ethanol (99.5) with deter- mined ethanol (C2H5OH) content. The relation between 15 speciˆc gravity d15 of ethanol and content of ethanol (C2H5OH) is 0.797 : 99.46 volz, 0.796 : 99.66 volz,and 0.795 : 99.86 volz. (2) Preparation of sample solution and standard solution Sample solution: Measure accurately a volume of sample at 15 ± 29C equivalent to about 5 mL of ethanol (C2H5OH), and add water to make exactly 50 mL. Measure accurately 25 mL of this solution, add exactly 10 mL of the internal standard solution, and add water to make 100 mL. Standard solution: Measure accurately 5 mL of ethanol for alcohol number at the same temperature as the sample, and add water to make exactly 50 mL. Measure accurately 25 mL of this solution, add exactly 10 mL of the internal standard solution, and add water to make 100 mL. (3) Procedure Place 25 mL each of the sample solution and the standard solution in a 100-mL, narrow-mouthed, cylindrical glass bottle sealed tightly with a rubber closure and aluminum band, immerse the bottle up to the neck in water, allowed to stand at room temperature for more than 1 hour in a room with little change in temperature, shake gently so as not to splash the solution on the closure, and allow to stand for 30 minutes. Perform the test with 1 mL each of the gas in the bottle with a syringe according to the Gas Chromatography <2.02> under the following conditions, and calculate the ratios, Q T and QS, of the peak height of ethanol to that of the internal standard. Q 5(mL) Alcohol number= T × QS a volume (mL) of sample ethanol (C2H5OH) content (volz)of ethanol for alcohol number × 9.406 Internal standard solution—A solution of acetonitrile (3 in 50). Fig. 1.01-1 Operating conditions— Detector: A hydrogen ‰ame-ionization detector. more than that shown in the above Table. Column: A glass tube about 3 mm in inside diameter and (iv) Other substances: Render preparations containing about 1.5 m in length, packed with 150- to 180-mmporous free ammonia slightly acidic with dilute sulfuric acid. If ethylvinylbenzene-divinylbenzene copolymer (mean pore volatile acids are present, render the preparation slightly size: 0.0075 mm, 500 – 600 m2Wg) for gas chromatography. alkaline with sodium hydroxide TS, and if the preparations Column temperature: A constant temperature between contain soap along with volatile substances, decompose the 1059C and 1159C. soap with an excess of dilute sulfuric acid before the extrac- Carrier gas: Nitrogen tion with petroleum benzin in the treatment described in (iii). Flow rate: Adjust the ‰ow rate so that the retention time of To the distillate add 4 to 6 g of potassium carbonate and 1 ethanol is 5 to 10 minutes. JP XV General Tests / Ammonium Limit Test 19 Selection of column: Proceed with 1 mL of the gas ob- tained from the standard solution in the bottle under the above operating conditions, and calculate the resolution. Use a column giving elution of ethanol and the internal standard in this order with the resolution between these peaks being not less than 2.0. 1.02 Ammonium Limit Test Ammonium Limit Test is a limit test for ammonium con- tained in drugs. In each monograph, the permissible limit for ammonium + (as NH4 ) is described in terms
Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • Download Download
    VOLUME 7 NOMOR 2 DESEMBER 2020 ISSN 2548 – 611X JURNAL BIOTEKNOLOGI & BIOSAINS INDONESIA Homepage Jurnal: http://ejurnal.bppt.go.id/index.php/JBBI IN SILICO STUDY OF CEPHALOSPORIN DERIVATIVES TO INHIBIT THE ACTIONS OF Pseudomonas aeruginosa Studi In Silico Senyawa Turunan Sefalosporin dalam Menghambat Aktivitas Bakteri Pseudomonas aeruginosa Saly Amaliacahya Aprilian*, Firdayani, Susi Kusumaningrum Pusat Teknologi Farmasi dan Medika, BPPT, Gedung LAPTIAB 610-612 Kawasan Puspiptek, Setu, Tangerang Selatan, Banten 15314 *Email: [email protected] ABSTRAK Infeksi yang diakibatkan oleh bakteri gram-negatif, seperti Pseudomonas aeruginosa telah menyebar luas di seluruh dunia. Hal ini menjadi ancaman terhadap kesehatan masyarakat karena merupakan bakteri yang multi-drug resistance dan sulit diobati. Oleh karena itu, pentingnya pengembangan agen antimikroba untuk mengobati infeksi semakin meningkat dan salah satu yang saat ini banyak dikembangkan adalah senyawa turunan sefalosporin. Penelitian ini melakukan studi mengenai interaksi tiga dimensi (3D) antara antibiotik dari senyawa turunan Sefalosporin dengan penicillin-binding proteins (PBPs) pada P. aeruginosa. Tujuan dari penelitian ini adalah untuk mengklarifikasi bahwa agen antimikroba yang berasal dari senyawa turunan sefalosporin efektif untuk menghambat aktivitas bakteri P. aeruginosa. Struktur PBPs didapatkan dari Protein Data Bank (PDB ID: 5DF9). Sketsa struktur turunan sefalosporin digambar menggunakan Marvins Sketch. Kemudian, studi mengenai interaksi antara antibiotik dan PBPs dilakukan menggunakan program Mollegro Virtual Docker 6.0. Hasil yang didapatkan yaitu nilai rerank score terendah dari kelima generasi sefalosporin, di antaranya sefalotin (-116.306), sefotetan (-133.605), sefoperazon (-160.805), sefpirom (- 144.045), dan seftarolin fosamil (-146.398). Keywords: antibiotik, penicillin-binding proteins, P. aeruginosa, sefalosporin, studi interaksi ABSTRACT Infections caused by gram-negative bacteria, such as Pseudomonas aeruginosa, have been spreading worldwide.
    [Show full text]
  • Hepcidin Therapeutics
    pharmaceuticals Review Hepcidin Therapeutics Angeliki Katsarou and Kostas Pantopoulos * Lady Davis Institute for Medical Research, Jewish General Hospital, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-(514)-340-8260 (ext. 25293) Received: 3 November 2018; Accepted: 19 November 2018; Published: 21 November 2018 Abstract: Hepcidin is a key hormonal regulator of systemic iron homeostasis and its expression is induced by iron or inflammatory stimuli. Genetic defects in iron signaling to hepcidin lead to “hepcidinopathies” ranging from hereditary hemochromatosis to iron-refractory iron deficiency anemia, which are disorders caused by hepcidin deficiency or excess, respectively. Moreover, dysregulation of hepcidin is a pathogenic cofactor in iron-loading anemias with ineffective erythropoiesis and in anemia of inflammation. Experiments with preclinical animal models provided evidence that restoration of appropriate hepcidin levels can be used for the treatment of these conditions. This fueled the rapidly growing field of hepcidin therapeutics. Several hepcidin agonists and antagonists, as well as inducers and inhibitors of hepcidin expression have been identified to date. Some of them were further developed and are currently being evaluated in clinical trials. This review summarizes the state of the art. Keywords: iron metabolism; hepcidin; ferroportin; hemochromatosis; anemia 1. Systemic Iron Homeostasis Iron is an essential constituent of cells and organisms and participates in vital biochemical activities, such as DNA synthesis, oxygen transfer, and energy metabolism. The biological functions of iron are based on its capacity to interact with proteins and on its propensity to switch between the ferrous (Fe2+) and ferric (Fe3+) oxidation states.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The
    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
    [Show full text]
  • Fluorescent Sensors for the Detection of Heavy Metal Ions in Aqueous Media
    sensors Review Fluorescent Sensors for the Detection of Heavy Metal Ions in Aqueous Media Nerea De Acha 1,*, César Elosúa 1,2 , Jesús M. Corres 1,2 and Francisco J. Arregui 1,2 1 Department of Electric, Electronic and Communications Engineering, Public University of Navarra, E-31006 Pamplona, Spain; [email protected] (C.E.); [email protected] (J.M.C.); [email protected] (F.J.A.) 2 Institute of Smart Cities (ISC), Public University of Navarra, E-31006 Pamplona, Spain * Correspondence: [email protected]; Tel.: +34-948-166-044 Received: 21 December 2018; Accepted: 23 January 2019; Published: 31 January 2019 Abstract: Due to the risks that water contamination implies for human health and environmental protection, monitoring the quality of water is a major concern of the present era. Therefore, in recent years several efforts have been dedicated to the development of fast, sensitive, and selective sensors for the detection of heavy metal ions. In particular, fluorescent sensors have gained in popularity due to their interesting features, such as high specificity, sensitivity, and reversibility. Thus, this review is devoted to the recent advances in fluorescent sensors for the monitoring of these contaminants, and special focus is placed on those devices based on fluorescent aptasensors, quantum dots, and organic dyes. Keywords: heavy metal ions; fluorescent sensors; fluorescent aptasensors; quantum dots; organic dyes 1. Introduction Monitoring the presence of contaminants in water is of general interest in order to ensure the quality of surface, ground, and drinking water [1,2]. Among the several water pollutants, such as plastic or waste [3], chemical fertilizers or pesticides [4], and pathogens [5], heavy metal ions are known for their high toxicity [6].
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka Et Al
    |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka et al. 45) Date of Patent: Apr. 13, 1993 (54) COMPOSITION AND METHOD FOR 4,528,295 7/1985 Tabakoff .......... ... 514/562 X REDUCING ACETALDEHYDE TOXCTY 4,593,020 6/1986 Guinot ................................ 514/811 (75) Inventors: Masayoshi Matsuoka, Habikino; Go OTHER PUBLICATIONS Kito, Yao, both of Japan Sprince et al., Agents and Actions, vol. 5/2 (1975), pp. 73) Assignee: Takeda Chemical Industries, Ltd., 164-173. Osaka, Japan Primary Examiner-Arthur C. Prescott (21) Appl. No.: 839,265 Attorney, Agent, or Firn-Wenderoth, Lind & Ponack 22) Filed: Feb. 21, 1992 (57) ABSTRACT A novel composition and method are disclosed for re Related U.S. Application Data ducing acetaldehyde toxicity, especially for preventing (63) Continuation of Ser. No. 13,443, Feb. 10, 1987, aban and relieving hangover symptoms in humans. The com doned. position comprises (a) a compound of the formula: (30) Foreign Application Priority Data Feb. 18, 1986 JP Japan .................................. 61-34494 51) Int: C.5 ..................... A01N 37/00; A01N 43/08 52 U.S. C. ................................. ... 514/562; 514/474; 514/81 wherein R is hydrogen or an acyl group; R' is thiol or 58) Field of Search ................ 514/557, 562, 474,811 sulfonic group; and n is an integer of 1 or 2, (b) ascorbic (56) References Cited acid or a salt thereof and (c) a disulfide type thiamine derivative or a salt thereof. The composition is orally U.S. PATENT DOCUMENTS administered, preferably in the form of tablets. 2,283,817 5/1942 Martin et al.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • COVID-19: Living Through Another Pandemic Essam Eldin A
    pubs.acs.org/journal/aidcbc Viewpoint COVID-19: Living through Another Pandemic Essam Eldin A. Osman, Peter L. Toogood, and Nouri Neamati* Cite This: https://dx.doi.org/10.1021/acsinfecdis.0c00224 Read Online ACCESS Metrics & More Article Recommendations *sı Supporting Information ABSTRACT: Novel beta-coronavirus SARS-CoV-2 is the pathogenic agent responsible for coronavirus disease-2019 (COVID-19), a globally pandemic infectious disease. Due to its high virulence and the absence of immunity among the general population, SARS- CoV-2 has quickly spread to all countries. This pandemic highlights the urgent unmet need to expand and focus our research tools on what are considered “neglected infectious diseases” and to prepare for future inevitable pandemics. This global emergency has generated unprecedented momentum and scientificefforts around the globe unifying scientists from academia, government and the pharmaceutical industry to accelerate the discovery of vaccines and treatments. Herein, we shed light on the virus structure and life cycle and the potential therapeutic targets in SARS-CoV-2 and briefly refer to both active and passive immunization modalities, drug repurposing focused on speed to market, and novel agents against specific viral targets as therapeutic interventions for COVID-19. s first reported in December 2019, a novel coronavirus, rate of seasonal influenza (flu), which is fatal in only ∼0.1% of A severe acute respiratory syndrome coronavirus 2 (SARS- infected patients.6 In contrast to previous coronavirus CoV-2), caused an outbreak of atypical pneumonia in Wuhan, epidemics (Table S1), COVID-19 is indiscriminately wreaking 1 China, that has since spread globally. The disease caused by havoc globally with no apparent end in sight due to its high this new virus has been named coronavirus disease-2019 virulence and the absence of resistance among the general (COVID-19) and on March 11, 2020 was declared a global population.
    [Show full text]
  • Chemistry Inventory; Fall
    CHEMISTRY FALL 2005 MSDS Mfg.'s Name Chemical Name Quantity Stored Storage Conditions (on file = 9) Aluminum 9 1.5 kg Aluminum chloride, anhydrous, 98.5% 9 0.2 kg Aluminum chloride · 6H2O 9 0.5 kg Aluminum hydroxide 9 0.5 kg Aluminum nitrate 9 0.5 kg Aluminum sulfate 9 0.5 kg Ammonia, concentrated 9 4.0 L Ammonium acetate 9 0.2 kg Ammonium chloride 9 Ammonium dihydrogen phosphate (monobasic) 9 0.4 kg J.T. Baker Ammonium hydrogen phosphate (dibasic) No 0.5 kg Ammonium nitrate 9 2.5 kg Ammonium oxalate 9 0.7 kg Ammonium peroxydisulfate 9 0.5 kg Ammonium sulfate 9 0.2 kg Antimony 9 0.4 kg Barium chloride, anhydrous 9 2.5 kg Barium chloride · 2H2O 9 2.5 kg Barium nitrate 9 0.8 kg Bismuth 9 2.0 kg Boric Acid 9 0.4 kg Brass 9 Bromine 9 2.5 kg Cadmium 9 0.1 kg Cadmium nitrate 9 0.3 kg Calcium acetate · xH2O 9 0.5 kg Calcium carbide 9 1.0 kg Calcium carbonate 9 2.2 kg Calcium chloride 9 1.0 kg Calcium hydroxide 9 0.3 kg Calcium nitrate · 4H2O 9 1.0 kg Calcium oxide 9 0.3 kg Calcium sulfate · 2H2O 9 1.0 kg Carbon 9 0.1 kg Ceric ammonium nitrate 9 0.5 kg Cesium chloride 9 0.01 kg Chromium 9 0.01 kg Chromium chloride 9 0.5 kg Chromium nitrate 9 0.5 kg Cobalt 9 0.025 kg Cobalt chloride 9 0.7 kg Cobalt nitrate 9 0.6 kg Copper (assorted) 9 4.0 kg Copper acetate 9 0.05 kg Copper chloride 9 0.1 kg Copper nitrate 9 3.5 kg Copper oxide 9 0.4 kg Cupric sulfate, anhydrous 9 0.5 kg Cupric sulfate · 5H2O 9 2.75 kg EDTA 9 0.6 kg Iodine 9 2.0 kg Iron (assorted) 9 5.0 kg MSDS Mfg.'s Name Chemical Name Quantity Stored Storage Conditions (on file = 9) Ferric ammonium
    [Show full text]